A new guidance document and a promise to hold a public workshop are just two commitments made by the US Food and Drug Administration in a new five-point action plan aimed at artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?